The Readout By Damian Garde Pfizer’s 95% vaccine efficacy, disappointment in ALS, & FDA promises of transparency
The Readout By Damian Garde Covid-19 vaccine data from Novavax & the future of peanut allergy treatment
The Readout By Damian Garde The year in biotech SPACs, AstraZeneca vs. Regeneron, & CRISPR gets $5 billion richer
The Readout By Meghana Keshavan A patent blow for Moderna, loosened Covid-19 regs, & the truth about inactive ingredients
The Readout By Damian Garde The saga of a ‘criminal’ short report, Moderna’s valuation, & UniQure’s patents
The Readout By Damian Garde Pfizer/BioNTech’s second vaccine, hemophilia advocates relieved, & is FDA more strict?
The Readout By Meghana Keshavan Sarepta’s gene therapy disappoints, beyond vaccines for mRNA, & what a Democratic Senate means for biotech
The Readout By Damian Garde A biotech rainmaker returns, Slaoui sticks around, & Pfizer edges ahead of Sarepta
The Readout By Damian Garde Biotech’s inaugural 2021 IPOs, Mukherjee’s new startup, & how the FDA can extend Warp Speed
The Readout By Meghana Keshavan The biotech 2021 preview, Pfizer to offer vaccine to placebo arm earlier, & a half dose of Moderna?
The Readout By Damian Garde 2020’s winning biotech VCs, UniQure’s safety alarm, & naming Moderna’s Covid-19 vaccine
The Readout By Meghana Keshavan Agios sells cancer arm, a disguised Novartis blessing, & a former FDA chief rises again
The Readout By Meghana Keshavan Moderna on track for EUA, J&J harassment allegations, & new antibodies tested for Covid-19
The Readout By Damian Garde Moderna’s big vaccine review, a diabetes drug for Alzheimer’s, & Trump’s loudest drug pricing opponent
The Readout By Damian Garde 2020’s worst biotech CEOs, how Moderna’s vaccine compares to Pfizer’s, & Sage’s new CEO
The Readout By Meghana Keshavan Let the vaccinations begin, AstraZeneca’s acquisition, & regulatory M&A
The Readout By Meghana Keshavan Sanofi’s stalled vaccine, Pfizer’s ad comm dissected, & condensate therapy
The Readout By Damian Garde How to watch Pfizer’s big vaccine test, J&J’s downsized study, & a press release worth $1 billion
The Readout By Damian Garde FDA endorses Pfizer’s Covid-19 vaccine, Vioxx gets closer to a return, & AstraZeneca’s data are still confusing
The Readout By Damian Garde A guide to Pfizer’s vaccine data dump, the CEOs standing up Trump, & diverging data in sickle cell disease
The Readout By Meghana Keshavan Sanguine ASH data, a remdesivir tax payout, & the reality of 20 million
The Readout By Meghana Keshavan Cytokine storms explained, on ending pharma gifts, & vaccines for the elderly
The Readout By Damian Garde What to watch for at ASH, Lilly’s Covid-19 revenue clears $1 billion, & Moderna pads rivals’ pockets
The Readout By Damian Garde Ovid’s lead drug fails, Trump schedules a vaccine summit, & nanotech’s big moment
The Readout By Damian Garde Moderna is worth more than Vertex, Google wins a biology bake off, & Regeneron looks to gene therapy for Covid-19
The Readout By Damian Garde Covid-19 could change trials forever, vaccines might not be lucrative long term, & Alnylam’s five-year journey
The Readout By Damian Garde AstraZeneca’s puzzling vaccine data, another Covid-19 IPO, & the end of a 14-year scientific saga
The Readout By Meghana Keshavan A third Covid-19 vaccine is effective & Resilience launches with $800M